Biomarkers to define the treatment end-point for pulmonary exacerbations in cystic fibrosis

定义囊性纤维化肺部恶化治疗终点的生物标志物

• 批准号: nhmrc : 1126973
• 负责人: A/Pr Robert Trengove
• 金额: $ 70.5万
• 依托单位: The University of Western Australia
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/biomarkers-define-treatment-cystic-fibrosis/947896
• 关键词: Biomarkers; define; treatment; end; point

Sensitive and reliable tests are required to monitor lung disease severity in cystic fibrosis. A number of potential methods have emerged in recent years. We will investigate how these tests track an acute episode of lung disease and determine whether, following a typical course of treatment, there is evidence of residual damage that contributes to overall progression of lung disease.

需要敏感和可靠的测试来监测囊性纤维化的肺部疾病严重程度。近年来出现了一些潜在的方法。我们将研究这些测试如何跟踪肺部疾病的急性发作，并确定在典型的治疗过程后，是否有残留损伤的证据有助于肺部疾病的整体进展。